An enveloped novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), single-stranded RNA betacoronavirus of the family *Coronaviridae,* has arisen from Wuhan, China, in late 2019 which posed global healthcare and economic threats \[[@CR1]\]. Recently, World Health Organization (WHO) named it coronavirus disease 2019 (COVID-19) and declared as a pandemic disease. Despite global containment and quarantine attempts, the reports regarding epidemiological and clinical characteristics of the disease are dramatically increased \[[@CR2]--[@CR4]\]. Despite promising preventive measures being taken, commercially there is no antiviral drugs or vaccine approved to prevent or treat the severe COVID-19 patients. Although numerous common clinical signs of the disease, i.e., dry cough, coryza, sore throat, dyspnea, myalgia, and fatigue, have been reported \[[@CR1], [@CR5]\], uncommon symptoms and signs have also been reported. Notably, in critical cases, respiratory failure sets in, leading to acute respiratory distress syndrome (ARDS) with multiorgan failure affecting renal and cardiac function and even death \[[@CR6]\]. On February 18, 2020, the first cluster of COVID-19 cases reported in Iran. Despite the application of public health measures, i.e., public education, travel restrictions, case management, contact management, school and daycare measures, and social distancing to reduce disease transmission, it is tremendously spread in the human populations throughout the country. Noteworthily, until May 25, 2020, there were 133,521 confirmed COVID-19 cases and 7359 deaths in Iran. Based on our multicenter experiences in the management of COVID-19 patients, we categorized the risks of opportunistic fungal infections in COVID-19 patients in Iran. In our investigations, the COVID-19 patient populations at the highest risk of opportunistic fungal infections are elderly patients suffering from ARDS, hospitalized in intensive care units (ICU), receiving broad-spectrum antibiotics, patients undergoing invasive or noninvasive ventilation, and those undergoing immunosuppressive or corticosteroid therapies. With this background in mind, we aimed to clarify some concerns regarding the SARS-CoV-2 infected patients were most likely to develop pulmonary aspergillosis, oral candidiasis, or pneumocystis pneumonia Fig. 1Clinical and diagnosis data of opportunistic fungal infections in COVID-19 patients

Among various factors leading to morbidity and mortality in COVID-19 patients, opportunistic bacterial or fungal infections could deteriorate the status of patients and leading to ARDS \[[@CR7]\]. Although it is not clearly understood, patients with severe COVID-19 are at similar risk of invasive fungal infections which has been already known in patients with severe influenza \[[@CR7], [@CR8]\], fungal infections in severely ill patients with COVID-19 in China, France, and Germany were diagnosed \[[@CR7]--[@CR9]\]. Notably on the first week of severely ill patients with COVID-19 admission, we observed several cases of putative oropharyngeal candidiasis (OPC), particularly those hospitalized in intensive care units (ICU) with low lymphocyte counts, under plasmapheresis, or total parenteral nutrition (TPN), due to common *Candida* species curable by fluconazole and nystatin \[[@CR10]\]. Moreover, in some critically ill COVID-19 patients with high level of lactate dehydrogenase (LDH), especially those undergoing immunosuppressive or corticosteroid therapies, based on radiological signs, *Pneumocystis jiroveci* pneumonia (PJP) were suspected. However, our observations were not supported by mycological, immunological and molecular assay. Remarkably, lymphopenia was the main laboratory finding in 85% of critically ill patients with COVID-19 \[[@CR6], [@CR11], [@CR12]\]. Tan et al. suggested lymphopenia might be a prognostic marker in these populations; patients who died due to COVID-19 had significantly lower lymphocyte counts rather than survivors or those with mild disease \[[@CR13]\]. Since the lymphocytes play a decisive role in maintaining immune homeostasis and defensive response against microbial invasion throughout the body, it might be hypothesized that inadequate lymphocyte count may be a key factor contributing to secondary fungal infections such as OPC and PJP in COVID-19 patients \[[@CR7], [@CR14]\]. However, clinical course and disease progression of COVID-19 is still poorly understood, there is no specific treatment with proven efficacy, and different therapeutic modalities are being performed. Considering treatment strategies in previous outbreaks of Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), proven invasive pulmonary aspergillosis were reported only in few cases of probable SARS cases and were associated with concomitant corticosteroid therapy \[[@CR15]\]. Nonetheless, corticosteroid therapy, i.e., hydrocortisone, dexamethasone, and methyl prednisolone, may raise the risk of secondary fungal infections in these patients \[[@CR16]\]. Interestingly, a systematic review and meta-analysis revealed a higher mortality rate in influenza patients who received corticosteroids, alongside an increased length of stay in intensive care (*p* \< 0.0001) and increased rate (RR 2.0, 95% CI 1.0--3.8; *p* = 0.04) of secondary bacterial or fungal infections \[[@CR17]\]. Thus, it seems that, coronavirus infection itself might not increase the risk for fungal infections, but other risk factors might have. Besides, using broad-spectrum antibiotics, either empirically or targeted therapy for super-infection in patients with severe COVID-19 raises the odds of fungal infections due to endogenous fungi such as *Candida* species \[[@CR18], [@CR19]\]. Meanwhile, it comes as no surprise that frequent antibiotics usage of meropenem or moxifloxacin in severely ill COVID-19 patients are effective against wide spectrum of bacteria, undoubtedly impair the balance of microorganisms resident in mucosal area, leading to further oral health complication \[[@CR19]\]. In a study from Chinese hospitals, the usage rate of antibiotics and antifungal agents in patients with severe COVID-19 was 100% and 39%, respectively \[[@CR18]\]. It is well known that ARDS triggered by viral pneumonia, influenza, or cytomegalovirus infections dramatically increases the risk for invasive pulmonary aspergillosis (IPA) even in immunocompetent patients probably due to the overexpression of anti-inflammatory cytokines, dysregulation of T-helper cell differentiation, and impaired cell-mediated immune response \[[@CR20], [@CR21]\]. Although we are yet to appreciate the incidence and role of IPA as a complication of severe COVID-19 disease in our observations, we have limited data to show how commonly IPA co-infection COVID-19 cases. It seems that more screening studies are highly recommended to evaluate the prevalence of IPA in severely COVID-19 patients \[[@CR9]\]. Therefore, the occurrence of IPA and other invasive mold infections are highly probable in COVID-19 patients, particularly in neutropenic patients, those prolongedly use broad-spectrum antibiotics, patients undergoing solid organ and hematopoietic stem cell transplantation (HSCT), those receiving intensive chemotherapy and patients with cystic fibrosis or chronic obstructive pulmonary disease (COPD) \[[@CR17], [@CR20], [@CR21]\]. Halo or reversed halo sign was hallmark of pulmonary mold infection in patients with severe influenza; radiological signs might be a valuable tool for diagnosis and management and should take into account for further diagnostic steps in COVID-19 patients \[[@CR9]\]. Remarkably, these radiographic patterns have not been previously documented in SARS and MERS patients, but are usually suggestive of IPA \[[@CR11], [@CR22]\]. Li et al. reported 'halo sign' patterns in chest CT examination of nine (18%) COVID-19 patients \[[@CR22]\]. However, the main pathological driver of this manifestation remains unknown, so far. In our opinion, physicians should pay attention to serious challenges associated with OPC, IPA, and PJP in COVID-19 critically ill patients. Nevertheless, due to overlapping clinical symptoms and menace posed by collection of respiratory samples using bronchoscopy that generates aerosolized droplets of SARS-CoV-2 \[[@CR23]\], patients with IPA and PJP co-infection are probably underdiagnosed and underreported. Diagnosis of fungal infections in Iran and developing countries with similar infrastructure is based on direct or histopathological microscopy and fungal cultures, but molecular assay, galactomannan, 1,3-β-[d]{.smallcaps}-glucan antigen testing, and other modern fungal diagnostics assays for further differentiating are rarely available in these region. Clinical and diagnosis data of fungal infections in COVID-19 patients are shown in Fig. [1](#Fig1){ref-type="fig"}. Differentiating fungal from bacterial infections based on clinical symptoms, physical findings, radiographic and routine laboratory results is matter of great difficulty. Thus suggesting, if secondary fungal infection is suspected, qualified specimens from the infection site, i.e., sputum or deeply coughed sputum, tracheal aspirates, bronchoalveolar lavage fluid (BAL), or oral swab specimens in case of OPC, should be collected to rule out fungal infections through culture and non-culture-based methods. Furthermore, serial assay of blood 1,3-β-[d]{.smallcaps}-glucan, serum and BAL galactomannan testing is crucially recommended to diagnose PJP and IPA alongside routine fungal examinations in suspected cases \[[@CR24]\]. In addition, in cases of fever refractory to antibiotic treatment, culture of catheter or peripheral venous blood samples should be timely performed in COVID-19 patients. Because untreated or inadequate treatment of cases increases chances of developing of fungal infection, with attendants significant increase in morbidity and mortality \[[@CR19], [@CR25]\]. Therefore, for critically ill patients with COVID-19 who have positive tests for opportunistic fungal infections which may have associated to their death, we have to pay attention to their managements based on national and international guidelines. However, it is imperative to wait the remaining ongoing clinical data to justify fungal complications on COVID-19 patients.
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